ArticleDiabetes/metabolism research and reviews2026
Abdominal MRI-Derived Liver, Visceral Fat, and Pancreatic Phenotypes Improve Prediction of Incident Type 2 Diabetes.
Article in Diabetes/metabolism research and reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
aimsTo evaluate whether abdominal magnetic resonance imaging (MRI)-derived metabolic phenotypes improve the opportunistic prediction of incident type 2 diabetes (T2D) beyond clinical risk models. MATERIALS AND
methodsThis study included 36,833 UK Biobank participants who underwent abdominal MRI and were free of T2D at imaging baseline. The original Cambridge Diabetes Risk Score (CDRS) was evaluated, and glycated haemoglobin (HbA1c) was added to form the clinical CDRS model. MRI phenotypes were selected using a LASSO-based selection-frequency analysis and added to construct the clinical CDRS-MRI model. Model performance was assessed in an internal validation set using Harrell's C-index, continuous net reclassification improvement (NRI), and integrated discrimination improvement (IDI).
resultsDuring a median follow-up of 7.38 years, 570 participants developed incident T2D. The selection-frequency analysis retained four MRI phenotypes: liver proton density fat fraction, liver volume, visceral fat volume, and pancreas volume. In the internal validation set, C-indices were 0.765 (95% CI, 0.731-0.800) for the original CDRS model, 0.820 (95% CI, 0.786-0.849) for the clinical CDRS model, and 0.849 (95% CI, 0.818-0.877) for the clinical CDRS-MRI model. The clinical CDRS-MRI model improved the C-index by 0.084 versus the original CDRS model and by 0.029 versus the clinical CDRS model, with a continuous NRI of 56.2% (95% CI, 40.6%-70.0%) and an IDI of 0.022 (95% CI, 0.010-0.037).
conclusionsAbdominal MRI-derived phenotypes improved the prediction of incident T2D beyond established clinical risk models. These findings support secondary use of available abdominal MRI data for metabolic risk stratification, pending external validation.
Indexed as
Identifiers
42823755What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.